Apixaban for Stroke Reduction in Atrial Fibrillation

Introduction to Apixaban

The American Heart Association/American Stroke Association recommends apixaban as a first-line therapy over warfarin for stroke prevention in patients with nonvalvular atrial fibrillation, providing superior stroke reduction, lower mortality, and significantly less major bleeding, with a Class I, Level of Evidence B recommendation 1, 2

For patients with nonvalvular atrial fibrillation and end-stage renal disease/dialysis (CrCl <15 mL/min), warfarin or dose-adjusted apixaban may be reasonable options, with apixaban being the only DOAC with supporting data in dialysis patients 3
Reduced dose: 2.5 mg twice daily is required when patients have at least 2 of the following characteristics: Age ≥80 years, Body weight ≤60 kg, with a citation supporting the dosing consideration 4

The ARISTOTLE trial demonstrated apixaban's superiority with a 51% reduction in hemorrhagic stroke when combined with other DOAC trials 5
Apixaban offers practical benefits, including no routine INR monitoring required, no dietary restrictions, fewer drug interactions, predictable pharmacokinetics, and lower discontinuation rates than warfarin 2, 4, 5

For patients with AF who have had an acute ischemic stroke, the timing of anticoagulation initiation depends on hemorrhagic transformation risk, with TIA patients initiating anticoagulation immediately, and high hemorrhagic risk stroke patients delaying initiation beyond 14 days 1, 5
The American College of Cardiology recommends considering the patient's renal function and hemorrhagic risk when initiating anticoagulation, with a citation supporting the consideration of renal function 3

When switching from apixaban to warfarin, discontinue apixaban, begin parenteral anticoagulant plus warfarin at the time of the next apixaban dose, and continue the parenteral agent until INR is therapeutic 3
Apixaban should be discontinued 48 hours before procedures with moderate-to-high bleeding risk and 24 hours before procedures with low bleeding risk, with bridging anticoagulation not generally required, although the specific details of bridging are not cited 1, 2, 5, 3

The American College of Cardiology recommends DOACs (including apixaban/Eliquis) over warfarin for eligible patients with AF due to their superior safety profile and at least non-inferior efficacy 6, 7
For patients with AF and elevated stroke risk (CHA₂DS₂-VASc score ≥2 in men or ≥3 in women), oral anticoagulants are strongly recommended by the American College of Cardiology 7, 8
The selection of anticoagulant should be based on stroke risk assessment, regardless of whether AF is paroxysmal, persistent, or permanent, as recommended by the American Heart Association 6, 9

The American College of Cardiology suggests that renal function should be evaluated before starting any DOAC and reassessed at least annually 6
For patients with end-stage CKD (CrCl <15 mL/min) or on dialysis with AF, warfarin or apixaban might be reasonable options, according to the American College of Cardiology 6, 10

DOACs, including apixaban, are contraindicated in patients with mechanical heart valves or moderate-to-severe mitral stenosis, as stated by the American College of Cardiology 7, 11
Dabigatran should not be used in patients with mechanical heart valves, according to the American Heart Association 6

Patients on warfarin require INR monitoring at least weekly during initiation and monthly when stable, as recommended by the American College of Cardiology 11
DOACs like Eliquis do not require routine coagulation monitoring but do require periodic assessment of renal and hepatic function, according to the American College of Cardiology 6, 7